Got Questions? Send us a message! We explore whether two old antiparasitics, fenbendazole and ivermectin, can meaningfully impact cancer by disrupting cell structure, metabolism, and immune signaling while challenging how drugs get approved and funded. We lay out the science, question the incentives, and call for trials that prioritize survival and quality of life. • Fenbendazole as a microtubule destabilizer leading to cell‑cycle arrest and apoptosis • Potential to bypass efflux pump resist...
Show more...